Recruiting NCT06654986
Muscle Anabolic Response to β2-adrenergic Stimulation With Increased Amino Acid Availability.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Salmeterol + amino acid availability, Salmeterol + placebo, Placebo + placebo.
- Who it may be relevant to
- Registry conditions: Healthy. Basic parameters: 18 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Denmark
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Importance of Amino Acid Availability in Modulating the Muscle Anabolic Response to β2-adrenergic Stimulation.
Overview
The purpose of the project is to investigate the effect of amino acid availability on the muscle anabolic response to beta2-adrenergic stimulation in young healthy men and women.
Interventions
- Drug Salmeterol + amino acid availability
The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device and 40 g amino acid availability (clear whey in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video. - Drug Salmeterol + placebo
The participants will be administered 200 µg salmeterol (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video. - Drug Placebo + placebo
The participants will be administered placebo (8 puffs) from a MDI device. Furthermore they will be administered 80 g placebo (carbo fuel in a shaker with water) daily during a 6-week intervention. Participants will be instructed to provide documentation of both the inhalation and the shaker intake via video.
Primary outcome measures
- Skeletal muscle hypertrophy [Time frame: Through study completion, an average on 7 weeks]
Secondary outcome measures (3)
- Quadriceps strength [Time frame: Through study completion, an average on 7 weeks]
- Power output during sprint testing [Time frame: Through study completion, an average on 7 weeks]
- Power output during time trial [Time frame: Through study completion, an average on 7 weeks]
Eligibility criteria
Inclusion criteria
- Age 18-40
- Physically active >5 hours a week
- Maximum oxygen uptake classified as high or very high
Exclusion criteria
- Active smoker currently or within the past 5 years
- Regular intake of medication deemed by the responsible study physician to affect the test parameters (hormonal contraception is accepted for women)
- Chronic or acute illness deemed by the responsible study physician to affect the test parameters
- Deviation from the study protocol
- Lean mass index >21 kg/m²
- Pregnancy
- Smoker
- Blood donation during the past 3 months
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Basic science
Study locations
Denmark · 1 center
- August Krogh Building — Copenhagen
Identifiers
NCT: NCT06654986 · SALM_chron